Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. Application Number 10/620,252 CHADEMA TRANSMITTAL Filing Date July 15, 2003 **FORM** First Named Inventor Garst Art Unit 1625 (to be used for all correspondence after initial filing) **Examiner Name** Morris, Patricia L. Attorney Docket Number 18 626-07-PA Total Number of Pages in This Submission **ENCLOSURES** (Check all that apply) After Allowance communication Fee Transmittal Form Drawing(s) to Technology Center (TC) Appeal Communication to Board Licensing-related Papers Fee Attached of Appeals and Interferences Appeal Communication to TC **√** Petition (Appeal Notice, Brief, Reply Brief) Amendment/Reply Petition to Convert to a Proprietary Information **Provisional Application** After Final Power of Attorney, Revocation Status Letter Affidavits/declaration(s) Change of Correspondence Address Other Enclosure(s) (please **Terminal Disclaimer** Identify below): **Extension of Time Request** Request for Refund **Express Abandonment Request** CD, Number of CD(s) Information Disclosure Statement Remarks Certified Copy of Priority Document(s) Response to Missing Parts/ Incomplete Application Response to Missing Parts under 37 CFR 1.52 or 1.53 SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Firm Gabor L. Szekeres Individual name Signature Date

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

<i></i>	Toni Whyte		
Signature	Soni Whyte	Date	5-19-04

Typed or printed name

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of Garst et al.) Art Unit 1625) Examiner: Morris, P. I	L.
Serial No.: 10/620,252))	
Filed: on July 15, 2003)	
For: PRODRUGS OF PROTON PUMP INHIBITORS)	

Certificate of Mailing

I hereby certify that this correspondence is being deposited on <u>May 19, 2004</u> with the United States Postal Service as first class mail in an envelope addressed to Commissioner for Patents, P.O.Box 1450, Alexandria VA 22313-1450 Mail Stop Non Fee Amendment

Tony Whyte

Date: 5-/9-04

AMENDMENT AND RESPONSE TO OFFICE ACTION

Commissioner for Patents **P.O.Box 1450** Alexandria VA 22313-1450

Dear Sir:

In response to the Requirement for Restriction dated April 22, 2004, applicant elects **Group I** of the claimed subject matter, as that group is

designated in the Requirement. The variable R in the elected group is shown by formulas (i) and (iii) in Claim 1.

In response to the Requirement for Election of Species applicant elects **Compound 9**, as a free acid or a pharmaceutically acceptable salt, such as the sodium salt. Compound 9 is shown by the formula below.

Compound 9

Compound 9 is described and shown, as applicable, on pages 75 - 77, 172 and 176 - 178 in the specification. On pages 75 - 77 Compound 9 is shown and described as a mixture with its isomer Compound 10, whereas on pages 172 and 176 - 178 the preparation of isomerically pure Compound 9 is described.

Claims 1, 3, 6 - 8, 10, 11, 13, 14, 18, 20, 21, 23, 24 and 28 - 32 read on the elected compound.

The Requirements for Restriction and Election of Species are respectfully traversed on the basis that, in applicant's opinion, a search directed to the entire subject matter of the claims would not present an undue hardship.

Please AMEND the above-identified application as follows:

IN THE CLAIMS: Please Cancel Claim 33 and amend Claims 1 and 16 as set forth below in the Complete Listing of All Pending Claims.